US4104387A
Expired / Lapsed
US
⏱️ 0.0 years remaining
3-(Arylcycloiminoalkyl)benzisothiazole 1,1-dioxides
Assignee: ER Squibb and Sons LLC
•
Filing: 1977-05-23
•
Granted: 1978-08-01
•
Expires: 1997-05-23
Abstract
Abstract 3-(Arylcycloiminoalkyl)benzisothiazole 1,1-dioxides are provided having the structure ##STR1## wherein R is hydrogen, halogen, lower alkyl, lower alkoxy or nitro; R 1 is hydrogen, lower alkoxy or halogen with the proviso that R 1 can be lower alkoxy or halogen only when R is lower alkoxy or halogen, respectively; A is O or NH; X is hydrogen, halogen lower alkyl, lower alkoxy, or trifluoromethyl; Y is C or N, where Y is C, is a double bond, and when Y is N, represents a single bond, B is an alkylene group containing 2 to 5 carbons in the normal chain; Q is a single bond or an alkylene group containing 1 to 3 carbons in the normal chain; and physiologically acceptable acid-addition salts thereof. These compounds are useful as antiinflammatory agents.
Inventors
- 👤 Peter C. Wade
- 👤 Thomas P. Kissick
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 08:54
CPC Classifications
C; C07; C07D; C07D275/00; C07D275/04; C07D275/06; C07D417/00; C07D417/02; C07D417/12
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
121 words
A compound of the structure ##STR28## wherein R is hydrogen, halogen, lower alkyl, lower alkoxy or nitro; R 1 is hydrogen, lower alkoxy or halogen with the proviso that R 1 can be lower alkoxy or halogen only when R is lower alkoxy or halogen, respectively; A is O or NH; X is hydrogen, halogen, lower alkyl, lower alkoxy, or trifluoromethyl; Y is C or N, where Y is C, represents a double bond, and when Y is N, represents a single bond, B is an alkylene group containing 2 to 5 carbons in the normal chain; Q is a single bond or an alkylene group containing 1 to 3 carbons in the normal chain; and physiologically acceptable acid-addition salts thereof.
Claim 2
Dependent Claim
121 words
A compound of the structure ##STR28## wherein R is hydrogen, halogen, lower alkyl, lower alkoxy or nitro; R 1 is hydrogen, lower alkoxy or halogen with the proviso that R 1 can be lower alkoxy or halogen only when R is lower alkoxy or halogen, respectively; A is O or NH; X is hydrogen, halogen, lower alkyl, lower alkoxy, or trifluoromethyl; Y is C or N, where Y is C, represents a double bond, and when Y is N, represents a single bond, B is an alkylene group containing 2 to 5 carbons in the normal chain; Q is a single bond or an alkylene group containing 1 to 3 carbons in the normal chain; and physiologically acceptable acid-addition salts thereof.
Claim 3
Dependent Claim
9 words
The compound of claim 1 having the structure ##STR29##
Claim 4
Dependent Claim
9 words
The compound of claim 1 having the structure ##STR30##
Claim 5
Dependent Claim
32 words
The compound of claim 2 wherein R is hydrogen, A is NH, B is (CH 2 ) 2 , Q is a single bond or CH 2 , and X is hydrogen.
Claim 6
Dependent Claim
32 words
The compound of claim 3 wherein R is hydrogen, A is O, B is (CH 2 ) 2 , Q is a single bond or CH 2 , and X is hydrogen.
Claim 7
Dependent Claim
29 words
The compound of claim 1 wherein A is --(CH 2 ) 2 -- or --(CH 2 ) 3 -- and Q is a single bond or CH 2 .
Claim 8
Dependent Claim
10 words
The compound of claim 1 wherein R 1 is hydrogen.
Claim 9
Dependent Claim
13 words
The compound of claim 7 wherein R is in the 5- or 6-position.
Claim 10
Dependent Claim
14 words
The compound of claim 1 having the name 3-[2-(4-phenyl-1-piperazinyl)ethoxy]-1,2-benzisothiazole, 1,1-dioxide or its hydrochloride salt.
Claim 11
Dependent Claim
10 words
The compound of claim 1 having the name N-[2-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)ethyl]-1,2-benzisothiazol-3-amine, 1,1-dioxide.
Claim 12
Dependent Claim
27 words
A composition which comprises a compound of claim 1 in a physiologically acceptable vehicle, said compound being present in an effective amount for treating an inflammatory condition.
Claim 13
Dependent Claim
22 words
A method for treating an inflammatory condition in a mammalian host, comprises administering an effective amount of the composition of claim 11.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-07-31 | 1982-01-30 | 1982-08-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-07-31 | 1986-01-30 | 1986-08-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-07-31 | 1990-01-30 | 1990-08-01 | $7700.00 | Window Closed / Lapsed |